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Abstract
A well-documented fact for a group of persistent, bioaccumulating organohalogens contaminants,
namely polychlorinated biphenyls (PCBs), is that appropriate regulation was delayed, on average,
up to 50 years. Some of the delay may be attributed to the fact that the science of toxicology was
in its infancy when PCBs were introduced in 1920's. Nevertheless, even following the development
of modern toxicology this story repeats itself 45 years later with polybrominated diphenyl ethers
(PBDEs) another compound of concern for public health. The question is why? One possible
explanation may be the low coherence between experimental studies of toxic effects in animal
models and human studies. To explore this further, we reviewed a total of 807 PubMed abstracts
and full texts reporting studies of toxic effects of PCB and PBDE in animal models. Our analysis
documents that human epidemiological studies of PBDE stand to gain little from animal studies due
to the following: 1) the significant delay between the commercialisation of a substance and studies
with animal models; 2) experimental exposure levels in animals are several orders of magnitude
higher than exposures in the general human population; 3) the limited set of evidence-based
endocrine endpoints; 4) the traditional testing sequence (adult animals – neonates – foetuses)
postpones investigation of the critical developmental stages; 5) limited number of animal species
with human-like toxicokinetics, physiology of development and pregnancy; 6) lack of suitable
experimental outcomes for the purpose of epidemiological studies. Our comparison of published
PCB and PBDE studies underscore an important shortcoming: history has, unfortunately, repeated
itself. Broadening the crosstalk between the various branches of toxicology should therefore
accelerate accumulation of data to enable timely and appropriate regulatory action.
Background
The history of research on a group of persistent, bioaccu-
mulating organohalogen environmental contaminants,
namely polychlorinated biphenyls (PCBs), shows serious
delays in the accumulation of necessary data for the pur-
pose of toxic-substance policy making and regulatory
action [1]. Delays averaging some 50 years, depending on
the country, have brought on far-reaching consequences
with damage to human health, natural ecosystems and
the economy [2]. The ever-increasing accumulation of
industrial contaminants in biota, the influence of which is
of yet unknown to human health, is one reason why
speeding up policy making and regulatory action is
becoming an important goal in the field of toxicology.
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utable to the low coherence between experimental studies
of toxic effects in animal models and human studies? In
other words, to what extent the outputs of animal studies
aid in the design of human studies? Animal models play
an important role in studying the toxic effects of hazard-
ous substances, determining dose-response relationships,
and pinpointing the most susceptible developmental
stages. The results of animal experiments form an impor-
tant input for human studies which influence directly the
policy making process. Any discordance between them
may slow down the regulatory process. Hence, an impor-
tant question is to what extent the outputs of existing ani-
mal experiments correspond to the input requirements for
human studies?
To answer this question, we compared the animal-study
histories of two groups of well known organohalogen
contaminants: PCBs and PBDEs (polybrominated diphe-
nyl ethers). PCBs have been relatively well studied com-
pared to PBDE which are a relatively new group with a
much shorter history of studies. In addition, we also ask
what lessons, if any, are to be drawn from history?
We reviewed PubMed titles, abstracts and full texts
selected with the terms "PCB" or "PBDE" as search criteria
on May 15th, 2008. All reports that dealt with animal
model experiments were selected then by reading availa-
ble texts (titles/abstracts/full texts). The following reports
of experiments with animal models were excluded from
the subsequent analysis: (1) in vitro experiments with ani-
mal cells and tissues; (2) reviews; (3) experiments whose
exposure was not controlled (field studies, exposure by
use of contaminated food with unknown concentration of
organohalogens, etc); (4) strictly toxicokinetic reports not
addressing health effects; (5) experiments using various
metabolites and derivatives of PBDEs and/or PCBs; (6)
experiments using heterogeneous mixtures of contami-
nants (i.e. mixtures consisting not only of PCB or PBDE
congeners). Mixtures of PBDEs or PCBs congeners were
included. In other words, only reports of in vivo animal
experiments addressing health effects of controlled expo-
sure to PCBs or PBDEs were selected. No other restrictions
were applied. 748 out of a total of 6076 PCB articles and
59 out of 649 PBDE articles met our selection criteria and
were retained for analysis (see Additional files 1 and 2).
All the data used further in this study were extracted from
titles, abstracts or full texts of all selected articles with the
priority given to more complete text.
It should be noted that PubMed databases do not effec-
tively capture the older scientific literature that predated
the internet and existed only in print media. Thus, the first
PCB studies we analysed were from 1971 [3,4] although
PCBs were commercialised in the 1920's. This limitation
is not so essential for analysis of PBDE papers due to their
much later arrival in the market. To avoid bias resulting
from limitations of electronic databases, the data are
expressed as a percentage of total articles in a given time
period.
Our study is not a systematic review but rather reflection
based on analysis of history. We analyse existing experi-
ments with animals in order to see if the level of coher-
ence with human studies can be a limitation for the
development of the latter.
What factors are important to permit the transfer of 
animal data to human studies?
In an attempt to approach existing animal data in a sys-
tematic fashion and determine whether they are compati-
ble with existing and ongoing epidemiologic
investigations on environmental contaminants, we
designed a non-exhaustive set of basic requirements in
order to better "harmonize" animal experiments for the
purpose of data transfer to human studies.
When considering animal toxicology studies with a view
to timely toxic-substance policy making and regulatory
action, "harmonized" experiments with animal models
should fulfill at least six basic requirements. These are
summarized below.
1. Experiments must be completed long before the sub-
stance can become a public health concern and well
enough in advance to allow timely policy making and reg-
ulatory action. Obviously, once a persistent, toxic sub-
stance has already accumulated in the environment, as
was the case with PCBs, the problem is greatly com-
pounded.
To study time-trends in animal research we analysed the
temporal distribution of all selected 748 PCB and 59
PBDE reports using the print publishing date with respect
to the dates of the beginning of production, initial detec-
tion in human tissues, and subsequent ban.
2. The doses studied must be relevant to human exposure
levels. Toxic effects and biomarkers drawn from exposures
several fold higher than the levels of exposure of the gen-
eral human population cannot be transferred directly to
the studies of the general population since most of toxic
substances exert different effects at different doses. More-
over, toxic effects obtained from dose-response studies
performed at high doses cannot be extrapolated to exist-
ing low-dose exposures of the general population. This is
so because a number of environmental toxicants display
non-linear dose-response relationships. Non-monotonic
dose-response curves were already reported for PCBs [5-7]
and for PBDEs [8-10]. Baseline corticosterone concentra-Page 2 of 18
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commercial mixture of PCBs (Aroclors) exhibited a
hormetic response in relation to total PCB liver burden
[5]. In one assay [6] rainbow trout exposed to low dose
(0.4 μg/egg) of another commercial PCB mixture (Clo-
phen A50) through eggs nanoinjections showed
decreased disease (trout fry syndrome) resistance while
resistance of group exposed to high dose (2 μg/egg) was
not significantly different from the control group. Pertur-
bations in the hypothalamic-pituitary-thyroid axis were
highly nonlinear with respect to PCB 126 dosing in study
by Fisher et al [7]. According to Gee and Moser [10]
number of open-field rears during a 1-minute observation
period was significantly higher in male mice exposed neo-
natally to a single oral dose of 1 mg/kg BDE-47 than in
control group as well as mice exposed to 10 and 30 mg/kg
BDE-47. Talsness et al [8] reported the increase in ovarian
weight in rats received prenatally 140 μg/kg bw but not
700 μg/kg of BDE-47. In our recent study [9] pups
exposed perinatally to 0.002 mg/kg BDE-47 appear to be
much more hyperactive on PND 20 than groups exposed
to 0.2 and 0.02 mg/kg. Biphasic and hormetic dose-
response curves are widely discussed in the toxicology lit-
erature [11,12] suggesting, for a majority of cases, the
involvement of heterogeneous mechanisms of response
to different threshold concentrations. Experimental test-
ing exclusively at only high doses can therefore lead to a
false sense of security with respect to the safety of a sub-
stance for the general population.
In short, the use of doses several fold higher than exposure
levels for the general human population contributes little
to our understanding of the risks incurred by that popula-
tion.
To analyse doses of PCB and/or PBDE used in animal
experiments we extracted, when available, data on dosing
protocols from all selected PCB and PBDE reports, namely
dose of compound per individual administration (daily
dose) and total number of administrations. Total dose
was calculated by multiplying daily dose by number of
administrations. An average daily and average total dose
was calculated for each year as mean ± SE for all experi-
ments reported in the respective year. In number of cases,
more than one experiment was presented in single paper.
We estimated as separate experiments, trials with animals
within one paper if they differed at least in one of the fol-
lowing: animal species/strains, treated stages of develop-
ment, administered compounds, daily exposure doses
and total exposure doses.
3. The most sensitive endpoints must be screened, i.e.
health effects emerging at the lowest exposure levels. Ade-
quate risk assessment for the general population must be
based on the analysis of toxic effects on the most sensitive
target organs and functions. Obviously it is impossible to
start research of new substance with unknown properties
with the most sensitive endpoints. It is thus necessary to
screen a series of endpoints to identify the most sensitive
as well as to use previously studied substances with simi-
lar structures (PCB for PBDE) to predict possible end-
points.
To detect health effects in the general population exposed
to low doses of environmental contaminants, biomarkers
of effect are essential. Biomarker epidemiology is under-
going a rapid development and expansion and is quickly
becoming one of the most promising areas of environ-
mental research [13]. Animal studies enable broader pos-
sibilities in the search of toxicity endpoints than does
epidemiological research on human populations. Indeed
it allows for the sacrifice of animals at any stage of devel-
opment, tissue harvesting as well as various other types of
interventions. Also animal experiments are not as costly
and robust as epidemiological studies. Thus, animal stud-
ies must uncover non-invasive biomarkers of low dose
exposure suitable for human studies.
Therefore, comprehensive screening of the most sensitive
endpoints and peripheral biomarkers of exposure is
another necessary requirement for animal studies.
We extracted data on the health effects of PCB or PBDE
exposure for each experiment of each selected article when
available and assigned them according to a slightly modi-
fied classification of the health effects used in ATSDR's
(US Agency for Toxic Substances and Disease Registry)
Toxicological Profiles. All effects were classified among
the following groups: mortality, respiratory, cardiovascu-
lar, gastrointestinal, haematological, musculoskeletal,
hepatic, renal, endocrine, dermal, ocular, metabolic,
other systemic, immunological and lymphoreticular, neu-
rological, reproductive, developmental effects, cancer and
genotoxicity. We modified the classifications with respect
to two aspects. First, endpoints dealing with endocrine
activity of reproductive organs were considered as endo-
crine rather than reproductive effects. Second, all end-
points addressing different organs at early stages of
development were assigned to the effect corresponding to
the organ rather than development and only growth
changes were considered as developmental, including
developmental malformations, developmental land-
marks and endpoints addressing foetal development.
4. The most sensitive stages of development must be
screened. A number of substances (including well-known
examples of ethanol and thalidomide) are known devel-
opmental toxicants at low doses but do not display toxic
properties for adults at the same concentrations. There-
fore, the most sensitive stages of development must bePage 3 of 18
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the most susceptible and vulnerable populations. Obvi-
ously, it is impossible to start research on a new substance
with unknown properties with the most sensitive stages. It
is necessary however to screen of most sensitive ages as
well as use already studied substances with similar struc-
ture (PCB for PBDE) to predict them. The particular sensi-
tivity of early developmental stages to PCB exposure was
shown in number of animal and human studies (see
reviews [14-17]). PBDE was shown recently to be of par-
ticular concern for early stages of development as being
potent neurodevelopmental toxin [18] and because of
higher levels of exposure in children than in adults [19-
22].
We extracted data on animal stages of development
exposed to PCB or PBDE from all selected articles when
available and assigned them to one of the following: pre-
natal exposure; neonatal exposure; perinatal exposure;
adult exposure. All these types of exposures were further
united into two groups: developmental exposures (pre-,
neo- and perinatal) and adult exposures. The temporal
distribution of experiments with different types of expo-
sure was analysed.
5. Ideally animal models should have human-like physi-
ology and toxicokinetics. Differences in toxicokinetics
predetermine different toxic effects in different species
[23]. For example, Geyer et al [24] estimated that BDE-47
has a terminal half life of 664 days in humans using daily
intake and total-body burden data. Terminal half life for
the same PBDE congener in mouse was calculated to be 23
days and it is rapidly excreted from the organism due to
mechanisms of active transport [25]. This difference in
toxicokinetics complicates transfer of health effects data
obtained in experiments with mouse to human studies,
while experiments with mouse average one third of total
number of published animal studies.
It is becoming increasingly clear that prenatal and neona-
tal stages of development are highly susceptible to a
number of toxic substances [1]. Therefore, not only is it
important to use animal models with human-like adult
physiology and toxicokinetics but also human-like preg-
nancy, pre-neonatal and neonatal development.
We extracted data on animal species used in each experi-
ment reported in selected articles to analyse time-trend
distribution of taxa in PCB and PBDE experiments.
6. Exposures must be verified by measurement of the
internal dose. For animal data to transfer correctly to
human studies, it is especially important to measure the
internal dose since exposure levels are rarely measured in
epidemiological studies and all the health effects are cor-
related with the internal dose.
There is no universally accepted protocol for the correct
estimation of internal dose of exposure. In fact, there is a
broad range of protocols using different tissues, time-
points, dose-parameters and chemical species. PBPK mod-
els are of use also. Given the large number of protocols for
determining of internal dose, we simply verified presence
or absence of any estimation of internal dose in the
selected articles.
We extracted from all selected papers, when available,
data on estimation of internal dose of the administered
substance in exposed animals. We considered that the
internal dose had indeed been estimated if there was any
type of measurement of residuals or metabolites of
administered congeners done at any time point in any tis-
sues of directly exposed animals or their offspring, in the
case of developmental exposures.
We used these basic requirements in order to "harmonize"
reports of animal experiments for the purpose of data
transfer to human studies. Our short list is by no means
exclusive and may be extended by others. We assume that
applying such requirements to the analysis of animal data
is the first step to document the level of coherence
between animal and human studies.
We also added the route of exposure to our analysis of
PCB and PBDE studies because it is, according to our per-
sonal experience, the subject of intense debate (in peer
review processes) with experts often displaying widely var-
ying opinions.
It is commonly accepted that studying the mechanisms of
toxicity greatly increases the relative value of animal
model studies. Albeit highly interesting in itself, knowl-
edge of toxicity mechanisms impacts only slightly on pol-
icy making and regulatory action. For instance, in spite of
some 30 years of intensive research, we are still unclear on
the specific mechanisms of PCB toxicity. What is clear,
however, is that this knowledge gap should not have pre-
cluded the ban on PCB in the 1970's. That is why our
short list does not include analysis of toxicity mechanisms
for harmonizing purposes.
Short history of PCB and PBDE
Both PCB and PBDE are ubiquitous, persistent organohal-
ogens. Until their ban in the 1970's, PCB accumulated in
biota. The bioaccumulation of PBDE, which are still mas-
sively produced, continues.
PCBs was first manufactured commercially in 1927. They
were used as coolants and insulating fluids for transform-Page 4 of 18
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coatings of electrical wiring and electronic components, as
pesticide extenders, as cutting oils, flame retardants,
hydraulic fluids, sealants (used in caulking, etc), adhe-
sives, wood floor finishes, paints, de-dusting agents, and
in carbonless copy paper. Manufacture peaked in the
1960's when the total global production of PCB was esti-
mated at 1.5 million tons per year [26]. In 1966, the
Swedish chemist Dr. Soren Jensen designated PCB as
ubiquitous environmental contaminants [27]. Global
PCB atmospheric emissions peaked at an estimated 400
tons per year by the early 1970's [28]. General Electric
(GE) alone had dumped between 0.5 to 1.5 million
pounds of PCB into the Hudson River by 1976 [29].
PCB-associated toxicity was recognized quite early due to
a variety of industrial incidents [30]. The most commonly
observed health effects on people exposed to PCB are skin
conditions such as chloracne and rashes. Studies on PCB-
exposed workers report changes in blood and urine, pos-
sibly pointing to liver damage. In 1968, PCB contamina-
tion of rice bran oil in Japan caused mass poisoning and
Yushô Disease in over 14,000 people [31]. Common
symptoms included dermal and ocular lesions, irregular
menstrual cycles, lowered immune response, fatigue,
headaches, cough, and unusual skin sores. Poor cognitive
development in children was reported at much lower
doses [32,33].
PCB production was banned in most countries during the
1970's, some 50 years after its commercial introduction in
the 1920's.
PBDE are a group of flame retardant chemicals which are
added to synthetic polymers. PBDE are thus found in var-
ious building materials, electronics, furnishings, motor
vehicles, plastics, polyurethane foams, and textiles. The
first patent for PBDE use as a flame retardant was issued
in 1960 and manufacturing of commercial products con-
taining PBDE begins in 1965 [34] several years before the
PCB ban. Total world demand for PBDE in 2001 was esti-
mated at 67,440 metric tons by the bromine industry [35].
PBDEs were first detected in the environment in 1979 [36]
and in biota in the 1980's [37]. Studies on North Ameri-
can wildlife report sharp increases in PBDE levels over a
20-year period, with levels doubling every 3 to 5 years [38-
41]. In human blood, milk, and tissues, total PBDE levels
have increased exponentially over the past 30 years, dou-
bling every 5 years [42].
Although their health effects, especially at low doses, need
to be studied further, PBDEs are nevertheless known to be
associated with neurodevelopmental toxicity and thyroid
hormone imbalance in rodents [18,43-47].
The European Union banned the use of penta- and octa-
BDE in 2004 and recently banned deca-BDE in 2008.
Penta-and octa-BDE were withdrawn from the North
American market in 2004 [48] but Deca-BDE still remains
in use in North America. Little is known with respect to
PBDE production in Asian countries. Waste and recycling
sites, indoor use of PBDE-containing products, and global
circulation of PBDE toward the northern hemisphere
from countries without policy, all contribute to the long
term persistence of PBDE in Europe and North America.
The introduction of PBDE coincided with the develop-
ment of the modern environmental movement inspired
partly by the scandalous story of PCB and including the
development of toxicological sciences, the establishment
of public environmental institutions and environmental
legislation in countries around the world.
However, more than 40 years elapsed between the start of
PBDE production in 1965 and the ban of most of the
PBDE congeners. Deca-BDE is still in use in North Amer-
ica, but unfortunately produces banned lower-bromi-
nated congeners by natural debromination via
photochemical reactions [49-51], anaerobic processes in
sludge and sediments [52,53] and metabolism in animals
[54-56].
Experimental timeline: too little too late?
The oldest experimental reports on PCB found through
our PubMed search were published in 1971. This likely
reflects the limitations of the electronic database rather
than the first toxicological studies of PCB. The number of
publications increased steadily every year thereafter (Fig
1A). The growing number of publications across the ear-
lier years may reflect the increasing proportion of the pub-
lished literature that is captured in PubMed as well as the
actual trend of research changing over time.
It is noteworthy that the number of PCB reports contin-
ued to rise despite PCB ban (in 1976 in the USA; and
1970's in most PCB-producing countries). The number of
publications peaked in 1984 and then again in 1994. The
first wave of interest was presumably triggered by current
exposures and observed toxic effects, whereas the next was
consecutive to emerging results from long-term epidemi-
ological studies on the general population.
The two oldest experimental studies on PBDE found
through our PubMed search were published in 1980
[57,58], several years after the PCB ban. In spite of these
reports of PBDE toxic effects and of the known structural
similarity of PBDE and PCB, there were only two publica-
tions between 1980 and 2001 – one in 1994 [59] and
another in 1996 [60] (Fig 1B). Renewed interest in PBDE
has been sustained since 2001 (see also [34]).Page 5 of 18
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Temporal distribution of studies addressing PCB (A) and PBDE (B) toxicity in experiments with animal modelsFigure 1
Temporal distribution of studies addressing PCB (A) and PBDE (B) toxicity in experiments with animal mod-
els.
Environmental Health 2008, 7:58 http://www.ehjournal.net/content/7/1/58Hence, intensive research only started once PBDE had
become ubiquitous, with high concentrations in biota. In
Sweden, PBDE concentrations in breast milk increased by
approximately two order of magnitude during last 30
years [42] and relatively high concentrations of PBDE
were found in almost every human and biota sample by
the early 1990's.
To characterise actual rate of studies: 161 PCB papers and
44 PBDE papers (27% of number of PCB papers) were
published during the last 5 years (2002–2007), while the
ban was completed for PCB approximately 30 years before
and was in the process for PBDE.
It took approximately 40 years to detect PCB in human tis-
sues since the start of production. The discovery of the
ubiquitous presence of PCBs in fat tissues of humans was
an important step in the recognition of their potential
danger. This discovery was delayed by the inability to
measure PCB residues with sensitive analytical methods.
The PCB designation as ubiquitous environmental con-
taminants occurred in 1966 [27], one year after the start of
PBDE production. It explains the decrease with time until
the discovery the ubiquitous presence of PBDE. The
period from substance detection in human tissues until
the ban accounted for approximately 10 years for PCB and
more than 25 years for PBDE (banning is not yet com-
pleted for this substance). Hence, the development of sen-
sitive analytical methods did not appear to have affected
the pace of environmental regulation for these substances.
Are study doses relevant to human exposure levels?
Over a 30-year period, the average daily PCB doses used in
experiments with animal models decreased steadily from
hundreds of milligrams per kilogram of bodyweight (mg/
kg bw) in the early 1970's, to hundreds of micrograms/kg
bw presently (Fig 2A). Meanwhile, human dietary daily
doses, at the period of highest exposure for the general
population, were estimated by the ATSDR at tens of nan-
ograms/kg bw. Daily exposure of the general population
is now estimated at picograms/kg bw. Therefore, in spite
of 30 years of decreasing PCB daily exposures, animal
experiments are still performed with doses several orders
of magnitude higher than human exposures. The resulting
graph does not change when the average total dose is used
instead of average daily dose (data not shown).
With the benefit of hindsight from the PCB experience,
investigators would be expected to choose PBDE doses
closer to human daily exposures. However, PBDE experi-
ments were nevertheless initially conducted (Fig 2B) with
high doses (tens of mg/kg bw) steadily decreasing to the
hundreds of micrograms/kg bw in 2005. Doses began to
rise once again despite the fact that the 2005 threshold
was known to be far above human exposures levels. In the
U.S., daily PBDE dietary intake in 2003–2004 was esti-
mated by Schecter et al. [20] at 0.2 μg/kg bw for nursing
infants, and 0.001 μg/kg bw for adults.
We hypothesize that doses increased after 2005 because
the no observed adverse effect level (NOAEL) was reached
at doses used in 2005. To test this hypothesis we tested the
developmental effects of subchronic exposures at low
doses of PBDE with rat and sheep animal models.
Pregnant rats were exposed to vehicle or low doses of
BDE-47 (2, 20 and 200 μg/kg bw), the most prevalent
PBDE congener found in human samples, by intravenous
injections every 5 days, from gestational day 15 to postna-
tal day 20. Hyperactivity and decreased total thyroxine in
offspring were observed in all tested groups [9]. Similarly,
pregnant sheep were exposed to vehicle or BDE-47 (0.2, 2
and 20 μg/kg bw), by intravenous injections weekly, from
the 5th to the 15th week of gestation. Decreased total triio-
dothyronine was observed in lambs of least exposed
group upon delivery [61]. BDE-47 content in adipose tis-
sue of mothers and offspring of both models was analyzed
and found to be similar to that reported for human popu-
lations. The observed effects indicate that doses even sev-
eral fold lower than those achieved in 2005 produce a
number of adverse effects. In view of these results, one
cannot help but wonder if it was the achieved NOAEL
which incited investigators to increase levels of exposure
in animal models, or rather the likelihood of "unpublish-
able" results?
The quest for the most sensitive endpoints
Each new environmental contaminant poses the challeng-
ing quest for sensitive endpoints of toxicity. In spite of the
large body of knowledge from toxicology, predicting the
toxic properties of new contaminants on the basis of their
chemical structure remains difficult. Systematic screening
of the most sensitive endpoints is necessary for each
potentially hazardous substance. The powerful new tools
of "omics" research which appeared over the last decades
will no doubt increasingly contribute to intensifying the
investigation into the sensitive endpoints of toxicity. Two
reports, both published in 2007, investigate PCB toxicity
using microarray technology [62,63]. Another 2006 arti-
cle reports the study of PBDE toxicity using proteomics
[64]. All other articles reviewed tested different endpoints
by traditional methods.
In general, similar profiles of endpoints are addressed in
PCB and PBDE studies (Fig 3). The range of endpoints is
relatively broader for PCB studies while experiments
addressing cancer, dermal, gastrointestinal, haematologi-
cal, musculoskeletal, ocular, renal, and respiratory effects
are missing in PBDE studies. One possible explanation forPage 7 of 18
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smaller total number of experiments.
Surprisingly, in spite of the important number of experi-
ments on PCB carcinogenicity, information on the carci-
nogenicity of PBDE in animal models is still lacking.
Although a number of studies indicate that certain conge-
ners exhibit aryl hydrocarbon receptor (Ah-R)-mediated
effects and are potent inducers of ethoxyresorufin-o-
deethylase (EROD), direct studies of the carcinogenic
properties of PBDE have yet to be reported.
Because of the well known endocrine disruptive proper-
ties of organohalogens, we considered endocrine end-
points in more detail (Fig 4). Despite the large number of
reports on endocrine endpoints, the diversity itself of the
studied endpoints is relatively limited and, surprisingly,
the same in PCB and PBDE studies. A disproportionately
large number of experiments address the hypothalamo-
pituitary-thyroid axis (202 for PCB and 98 for PBDE stud-
ies), whereas only a few studies address the hypothalamo-
pituitary-adrenal axis (22 for PCB and 8 for PBDE stud-
ies). This is surprising in view of the fact that the adrenal
Temporal trends toward decrease of average daily dose in experiments with animal modelsFigure 2
Temporal trends toward decrease of average daily dose in experiments with animal models.  A – experiments 
addressing PCB toxicity; B – experiments addressing PBDE toxicity.   Page 8 of 18
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esses in the human organism, and b) is the target for envi-
ronmental PCB [65]. Research into the effects of PBDE on
the adrenal gland is thus seriously lacking. But why is this
so?
One possibility is that the adrenal gland is insensitive to
organohalogens. To test this hypothesis, we studied adre-
nal endpoints of low-dose PBDE toxicity in our develop-
mental subchronic exposure rat model described
hereinabove [9]. In the offspring of group exposed to 0.2
mg/kg bw BDE-47 we observed decreased corticosterone,
adrenal atrophy, impaired adrenal zonation and impaired
expression of steroidogenic enzymes. These results show
that the adrenal gland is probably among the most sensi-
tive targets of PBDE toxicity. Hence, lack of attention to
the adrenal gland, as opposed to the thyroid gland, could
be due simply to tradition.
Numerous PCB and PBDE studies report a correlation
between level of exposure and different biomarkers of
effect which, theoretically, could be used in human stud-
ies. However a closer analysis of these outcomes indicates
three major limitations. First, the range of peripheral
biomarkers of toxicity is limited. Second, the overwhelm-
ing majority of experiments use exposure levels several
fold higher than exposure levels in the human popula-
tion. Outcomes are thus effects of acute toxicity rather
Distribution of endpoints of PCB and PBDE toxicity addressed in experiments with animal modelsFigure 3
Distribution of endpoints of PCB and PBDE toxicity addressed in experiments with animal models.Page 9 of 18
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Distribution of endocrine endpoints of PCB (A) and PBDE (B) toxicity addressed in experiments with animal modelsFigure 4
Distribution of endocrine endpoints of PCB (A) and PBDE (B) toxicity addressed in experiments with animal 
models.
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the general population. Lastly, most outcomes determina-
tion requires sacrifice of animals and thus they are inap-
plicable to human studies, such as measurements of liver
microsomal enzyme activities. Hence, our findings are in
perfect concordance with ATSDR Toxicological Profile for
PCB: "There are no specific biomarkers of effects for PCBs.
Numerous studies have attempted to correlate serum PCB levels
with liver-associated enzymes in PCB-exposed workers and gen-
eral population subjects; however, no conclusive association has
been found [66-77]. Further studies to identify specific biomar-
kers of effects of PCBs would facilitate medical surveillance
leading to early detection of potentially adverse health and pos-
sible treatment." (p. 499, [78]). Only thyroid hormone is
indicated in the profile for PBDE [79] as a biomarker of
effect with the notation that it is highly non specific.
It has to be mentioned that all the references cited in the
above paragraph are attributed to epidemiological stud-
ies. Our review of 807 PCB and PBDE experimental
reports also revealed no single study especially designed
and aimed at the investigation of outcomes suitable for
epidemiological studies. This further underscores the lack
of integration of the various branches of the field of toxi-
cology.
Screening for the most sensitive stages of development: a 
paradigm shift?
It was shown for a number of environmental contami-
nants, including PCB and PBDE, that the early stages of
development are much more sensitive than adulthood
[80,81]. Thus top-priority should be given to experiments
aimed at screening for the most sensitive stages of devel-
opment in order to identify and protect the most vulnera-
ble segment of the human population. However, this
represents an important shift for researchers and brings
into question traditional testing sequences.
The ratio of developmental versus non-developmental
experiments per year are summarized in Figure 5. The pro-
portion of studies using developmental models instead of
adult testing increased gradually in PCB studies (β = 1.08;
p = 0.01), the same trend was observed for PBDE reports
(β = 1.87; p = 0.16). Moreover, the number of pre- and
perinatal exposures versus neonatal exposures increased
within PCB developmental experiments (β = 1.36; p =
0.004). The number of PBDE reports is too small to con-
clude any similar trend.
Hence, investigators test adult animals before the more
susceptible neonates. Foetuses, which are in fact the most
susceptible, are tested last whereas they should logically
be tested first.
Animal models: are we using enough species?
The diversity of the taxonomic groups used as animal
models for both PCB and PBDE studies is shown in Figure
6, including detailed mammalian models. While there is
some diversification of large taxonomic groups used as
animal models over the last years, there is also an oppo-
site trend within mammalian models.
Rodents are thus becoming the sole mammalian order
used in most toxicological experiments. Each animal
model presents advantages and limitations depending on
the endpoints of interest. Advantages and role of rodent
models in toxicological studies are well known. The use of
the rodent models only in experimental toxicology is not
sufficient however, since rodent models have some limi-
tations, not covered in modern studies by any other spe-
cies. For example, speaking about PCB and PBDE it has to
be mentioned, that organohalogen toxicokinetics is very
different in rodents and humans [82]. Rodents differ also
in a number of important parameters for the study of
developmental toxicity [83], including physiology of
pregnancy, pre- and neonatal development.
Although primates are the ideal model to simulate human
physiology, development and toxicokinetics, their use is
dwindling for ethical and financial considerations. An
important problem stems from the fact that no other
group with human-like parameters is used in most toxico-
logical studies. Although having limitation as precocial
species certain mammals of the Artiodactyla order (even-
toed ungulates) are presumably good models for simulat-
ing human-like pregnancy and toxicokinetics [84], there
are unfortunately few reports of PCB studies and none, to
our knowledge, of PBDE studies using hoofed mammals.
The detailed discussion of animal species better corre-
sponding to diverse demands of thorough simulation of
humans in toxicological experiments is out of frames of
this survey. The revealed tendency of using just mice and
rat is obviously negative.
Quality control: the internal dose in exposed animals?
The choice of dosing paradigm is a challenge. Estimation
of the internal dose is thus a means of "quality control"
and yields valuable information for the transfer of data
from animal to human studies [85].
The data on estimation of internal doses in PBDE and PCB
studies are summarized in Figure 7. This documents that
lesson from PCB investigations was exceptionally trans-
ferred to PBDE studies. However, whereas measurement
of internal dose is increasing rapidly in PBDE studies (β =
6.32; p = 0.01), it surprisingly tends to decrease slowly in
PCB studies (β = -0.33; p = 0.09).Page 11 of 18
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Trends towards increase in number of developmental experiments versus experiments with adult animalsFigure 5
Trends towards increase in number of developmental experiments versus experiments with adult animals. A – 
developmental experiments addressing PCB toxicity; B – developmental experiments addressing PBDE toxicity; C – increase in 
number of pre- and perinatal versus neonatal exposures within developmental experiments with PCB.
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Distribution of animal species in experiments addressing PCB (A, C) and PBDE (B, D) toxicityFigure 6
Distribution of animal species in experiments addressing PCB (A, C) and PBDE (B, D) toxicity. A, B – big taxo-
nomic groups, C, D – mammalian models.
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Temporal trends in percent of studies using estimation of internal dose in animal modelsFigure 7
Temporal trends in percent of studies using estimation of internal dose in animal models. A – studies addressing 
PCB toxicity; B – studies addressing PBDE toxicity.
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The two major routes of exposure used in experiments
with animals are the oral routes and via injections. Both
routs named here are generic as oral administration may
be performed by oral gavage or by addition of the sub-
stance to food; injections include subcutaneous, intrave-
nous and intraperitoneal and may be further divided by
point of injection. Each certain type of substance admin-
istration has its unique advantages and disadvantages.
However the main advantage of all oral routes is that they
better mimic natural conditions of exposure (at least for
organohalogens) and are less stressful for animals. Oral
routes add uncertainty to the estimation of exposure since
rate of absorption and transformation of substance in the
intestine are often poorly known. On the contrary generic
routes via injections allow for better control of the internal
dose, especially at low doses. They do not simulate in
majority of cases environmental exposures however and
are stressful.
According to the data summarized in Figure 8, there is a
clear tendency to transfer from oral routes to injections in
PCB studies (β = 1.09; p < 0.0001). Surprisingly, only 4
PBDE studies reported using injections. Thus PCB and
PBDE studies seem to be at odds with respect to route of
exposure.
Conclusion
Critical analysis of reports of PCB and PBDE toxicity test-
ing in animal models shows that the logistics of toxicolog-
ical experiments makes animal data difficult to transfer to
human studies. Moreover, analysis of the history of ani-
mal studies shows that the hindsight offered by PCB
experimental history had little impact on experimental
toxicology and future investigations into PBDE. Indeed
the studies on PBDE display the same flaws as their PCB
counterparts, indicating that lessons were not drawn from
the history of PCB.
One important inconsistency between animal and human
research was shown recently in a critical review of PCB
experimental studies [85]: the lack of animal data on sev-
eral persistent congeners which are currently used as a
measure of human exposure while experimental studies
in animals are frequently conducted with commercial
PCB mixtures, a test design that does not reflect the expo-
sure situation in humans.
For animal-model data to benefit human studies, our sur-
vey highlights that the following important lessons must
be drawn.
• Intensive animal testing must precede marketing of a
new substance or be concomitant to its arrival upon the
market in order to avoid contamination of the environ-
Temporal trend towards increase in number of exposures via injections versus oral exposures in PCB experimentsFigure 8
Temporal trend towards increase in number of exposures via injections versus oral exposures in PCB experi-
ments.Page 15 of 18
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hazardous properties. As research activity is dependent on
funding this lesson is relevant not only for toxicologist but
for organizations providing financial support.
• Toxic effects in experimental studies are obtained at lev-
els of exposure several orders of magnitude higher than
exposure levels of the general population, preventing
direct transfer of animal results to human studies. Hence,
there is a need for toxic-substances testing with doses rel-
evant to human exposures and measurement of internal
dose.
• There is a need to use animal species with human-like
toxicokinetics and physiology of development and preg-
nancy. Rodents are becoming the sole model for toxico-
logical experiments. Toxic effects investigation, especially
in developmental toxicology, should extend to other
mammalian species.
• For endocrine disruptors, all endocrine glands must be
addressed. The role of environmental contaminants in
increasingly prevalent endocrine disorders such as child-
hood obesity and diabetes mellitus is an important
research avenue.
• According to the existing paradigm, investigation into
the most sensitive stages of development occurs in the fol-
lowing sequence: adult animals – neonates – foetuses.
However, the reverse sequence would accelerate data
accumulation for risk assessment.
• Animal experiments specifically designed to uncover
outcomes suitable for epidemiological research are
needed. There is increasing demand for this information
to design human studies.
We conclude that poor integration of the human and
experimental branches of toxicology can and does hamper
use of data obtained in experiments with animal models.
Hence, broadening of the dialogue between the various
branches of the field of toxicology is needed.
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